Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Information Technology

Harpoon Therapeutics

Che-Leung Law

Wendy Chang

Luke Walker

Banmeet Anand

Grace Wang

Alpana Naresh

Meghan Kellam

Haibo Wang

Rick Austin

Annie Winterhall

Bryan Lemon

The leadership team at Harpoon Therapeutics has a history of experience in various companies and industries, including Chief, Bruin Biometrics, LLC, Onyx Pharmaceuticals, Deloitte Consulting, and Amgen. They also have a variety of educational backgrounds, including Neuropsychology from the University of Pennsylvania, Finance from the London Business School, Genetics from the University of California, Davis, and Biotechnology from Texas A&M University.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at Harpoon Therapeutics

Board of Directors

CEO and Executive Team